The future of vagus nerve stimulation (VNS) as a therapy for chronic heart failure remains uncertain following the release of data from Boston Scientific Corp.’s NECTAR HF
trial and LivaNova PLC’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?